Advertisement
AMGN vs GILD
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) Stock Comparison
Key Takeaways
- Amgen (AMGN) and Gilead Sciences (GILD) both operate in the biotechnology sector with strong pipelines in oncology, infectious diseases, and rare conditions.
- Recent market activity shows Amgen (AMGN) benefiting from positive clinical data and earnings beats, while Gilead Sciences (GILD) has secured multiple regulatory approvals in HIV and liver disease.
- Amgen (AMGN) reported robust Q2 2026 revenue growth exceeding $10 billion with raised full-year guidance, driven by key products including Imdelltra.
- Gilead Sciences (GILD) demonstrated base business growth of 10% year-over-year in Q2 2026, supported by HIV franchise expansion and new FDA approvals such as Bixlenvo and Hepcludex.
- Relative performance reflects sector dynamics, with both stocks exhibiting volatility tied to clinical readouts and competitive developments over recent weeks.
- Market positioning highlights trade-offs in growth drivers, with Amgen (AMGN) emphasizing oncology momentum and Gilead Sciences (GILD) focusing on HIV prevention and treatment advancements.
Introduction
Amgen (AMGN) and Gilead Sciences (GILD) represent prominent players in the biotechnology industry, each with established portfolios and active pipelines addressing high unmet medical needs. This comparison examines their recent stock behavior, business fundamentals, and market sentiment within the current environment. Investors and traders seeking exposure to innovative therapies in oncology, infectious diseases, and related areas may find this analysis relevant for evaluating relative positioning. The focus remains on observable performance metrics and developments from recent market activity to provide a balanced view of how these stocks have responded to shared sector influences.
Amgen Overview and Recent Performance
Amgen (AMGN) develops and commercializes therapies primarily in oncology, cardiovascular disease, and inflammation. The company’s recent performance has been shaped by strong commercial execution across its growth drivers, which collectively expanded 26% year-over-year in the second quarter. Imdelltra (tarlatamab-dlle) recorded significant sales increases, supported by positive Phase 3 overall survival data in lung cancer and an FDA approval reducing monitoring requirements for initial doses. Despite a temporary share price decline linked to a competitor’s trial outcome, broader sentiment has remained constructive amid raised 2026 revenue and earnings guidance following the earnings beat. Stock levels have hovered near recent highs around $385–$390 amid ongoing pipeline progress.
Gilead Sciences Overview and Recent Performance
Gilead Sciences (GILD) focuses on antiviral therapies, oncology, and liver disease treatments. Recent market activity reflects momentum from its HIV franchise, including Biktarvy and the PrEP portfolio, alongside oncology contributions from Trodelvy. The company secured FDA approvals for Bixlenvo in HIV treatment and Hepcludex for hepatitis delta virus infection, alongside expanded voluntary licensing agreements for lenacapavir-based prevention in additional regions. Q2 2026 results showed 10% base business growth, prompting an upward revision to full-year HIV growth expectations. Shares have traded near $150, with sentiment supported by these regulatory milestones and commercial trends in the recent period.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed to navigate thousands of tickers across varying market conditions. While hundreds of such bots exist with diverse trading styles, strategies, timeframes, and performance statistics, only those demonstrating the strongest alignment with prevailing conditions appear in the Trending AI Robots section. Available bots span a range of metrics, including varying win rates, drawdown profiles, and ticker-specific focus areas, allowing users to explore options suited to different risk tolerances and objectives. This resource provides traders with data-driven insights into automated strategies. Review the Trending AI Robots page for current selections and detailed performance information.
Head-to-Head Comparison
Amgen (AMGN) and Gilead Sciences (GILD) differ in primary therapeutic emphases, with Amgen (AMGN) allocating substantial resources to oncology and inflammation assets while Gilead Sciences (GILD) maintains leadership in HIV and antiviral markets alongside oncology expansion. Growth drivers contrast through Amgen (AMGN)’s recent emphasis on Imdelltra acceleration versus Gilead Sciences (GILD)’s HIV PrEP and treatment portfolio scaling. Recent momentum has favored both through pipeline catalysts, though Amgen (AMGN) experienced a sharper reaction to external competitive news. Risk factors include clinical trial outcomes and regulatory timelines for each, with sector exposure centered on biotechnology innovation. Market sentiment reflects steady institutional interest in both, tempered by valuation considerations and broader healthcare dynamics.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, pipeline catalyst density, and relative trend stability in recent market activity, Tickeron’s AI models would currently assign a modestly higher probability to Amgen (AMGN) over Gilead Sciences (GILD) for near-term positioning. This assessment incorporates Amgen (AMGN)’s demonstrated revenue beat and guidance uplift alongside sustained oncology momentum, while acknowledging Gilead Sciences (GILD)’s regulatory successes. The evaluation remains probabilistic and subject to evolving data inputs rather than a definitive recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and GILD is a Buy.
AMGN | GILD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 11 | |
SMR RATING 1..100 | 15 | 96 | |
PRICE GROWTH RATING 1..100 | 41 | 45 | |
P/E GROWTH RATING 1..100 | 28 | 72 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (7) in the Biotechnology industry is in the same range as GILD (9). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's Profit vs Risk Rating (8) in the Biotechnology industry is in the same range as GILD (11). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for GILD (96). This means that AMGN’s stock grew significantly faster than GILD’s over the last 12 months.
AMGN's Price Growth Rating (41) in the Biotechnology industry is in the same range as GILD (45). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
AMGN's P/E Growth Rating (28) in the Biotechnology industry is somewhat better than the same rating for GILD (72). This means that AMGN’s stock grew somewhat faster than GILD’s over the last 12 months.
| AMGN | GILD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 46% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 31% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 47% | 2 days ago 64% |
| Advances ODDS (%) | 2 days ago 61% | 2 days ago 64% |
| Declines ODDS (%) | 6 days ago 47% | 6 days ago 49% |
| BollingerBands ODDS (%) | 2 days ago 63% | N/A |
| Aroon ODDS (%) | 2 days ago 43% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while GILD’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- GILD’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +6.35% price change this week, while GILD (@Pharmaceuticals: Major) price change was +1.10% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.57%. For the same industry, the average monthly price growth was -4.15%, and the average quarterly price growth was +11.36%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
GILD is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.57% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | +0.85% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.48% | ||
| GILD - AMGN | 52% Loosely correlated | +0.85% | ||
| PFE - AMGN | 51% Loosely correlated | +0.17% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.73% | ||
| MRK - AMGN | 47% Loosely correlated | -0.06% | ||
More | ||||